Molecular Partners' strategic partner Allergan completed patient recruitment in both abicipar pegol nAMD Phase 3 studies

Zurich-Schlieren, May 9, 2017. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin®* therapies, today announces that its partner Allergan has completed the patient recruitment in the two global AMD Phase 3 studies of abicipar pegol.

"We are impressed by the high recruitment speed that our colleagues from Allergan have accomplished and look forward to the 1-year data to be presented in 2018," commented Michael T. Stumpp, PhD, Chief Scientific Officer of Molecular Partners.

Patrick Amstutz, PhD, acting CEO of Molecular Partners added: "This is a major milestone for Molecular Partners and the whole DARPin® product pipeline. I would like to congratulate all teams involved, both here at Molecular Partners and at Allergan for this tremendous achievement."

Abicipar is an investigational drug for the treatment of retinal diseases such as neovascular AMD (nAMD), a leading cause of blindness in the western world. Abicipar may allow for less frequent dosing compared to currently approved anti-VEGF treatments which require monthly or bi-monthly injections into the eye.

The phase 3 program includes two studies, CEDAR and SEQUOIA, each planned to recruit 900 patients. The studies will evaluate the efficacy and safety of abicipar versus ranibizumab (Lucentis®) and the potential of abicipar to be dosed every 8 or 12 weeks vs. ranibizumab every 4 weeks. Top-line data are expected in 2018.


Media Release (PDF)



Provider
Channel
Contact
Tensid EQS Ltd., Switzerland
www.tensid.ch


newsbox.ch
www.newsbox.ch


Provider/Channel related enquiries
marco@tensid.ch
+41 41 763 00 50